141 related articles for article (PubMed ID: 25488854)
1. Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy.
Parving HH; Rossing P
Nat Rev Nephrol; 2015 Feb; 11(2):68-70. PubMed ID: 25488854
[TBL] [Abstract][Full Text] [Related]
2. Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy.
Boels MG; Avramut MC; Koudijs A; Dane MJ; Lee DH; van der Vlag J; Koster AJ; van Zonneveld AJ; van Faassen E; Gröne HJ; van den Berg BM; Rabelink TJ
Diabetes; 2016 Aug; 65(8):2429-39. PubMed ID: 27207530
[TBL] [Abstract][Full Text] [Related]
3. Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
Ortiz A; Fernandez-Fernandez B
Clin J Am Soc Nephrol; 2021 Dec; 16(12):1775-1778. PubMed ID: 34853063
[No Abstract] [Full Text] [Related]
4. Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
Smeijer JD; Kohan DE; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2023 Aug; 25(8):2419-2422. PubMed ID: 37157922
[No Abstract] [Full Text] [Related]
5. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL
Diabetes Obes Metab; 2017 May; 19(5):749-753. PubMed ID: 28019071
[TBL] [Abstract][Full Text] [Related]
6. Atrasentan for the treatment of diabetic nephropathy.
Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
[TBL] [Abstract][Full Text] [Related]
7. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Kröpelin TF; de Zeeuw D; Andress DL; Bijlsma MJ; Persson F; Parving HH; Heerspink HJ
Clin J Am Soc Nephrol; 2015 Mar; 10(3):410-6. PubMed ID: 25568217
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
[TBL] [Abstract][Full Text] [Related]
9. Endothelin receptor blockade in patients with diabetic nephropathy.
Rabelink TJ; Kohan DE
Contrib Nephrol; 2011; 172():235-242. PubMed ID: 21894003
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis.
Yuan W; Li Y; Wang J; Li J; Gou S; Fu P
Nephrology (Carlton); 2015 Jul; 20(7):459-66. PubMed ID: 25753148
[TBL] [Abstract][Full Text] [Related]
11. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Circulation; 2004 Aug; 110(8):921-7. PubMed ID: 15302780
[TBL] [Abstract][Full Text] [Related]
12. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
13. New strategies to tackle diabetic kidney disease.
Batu Demir D; Cooper ME
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):348-54. PubMed ID: 27138228
[TBL] [Abstract][Full Text] [Related]
14. Comparison of exposure response relationship of atrasentan between North American and Asian populations.
Heerspink HJ; Makino H; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Davis JW; Idler K; Kohan DE; Liu M; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
Diabetes Obes Metab; 2017 Apr; 19(4):545-552. PubMed ID: 27981738
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?
Wu T; McGrath KC; Death AK
Vasc Health Risk Manag; 2005; 1(4):309-16. PubMed ID: 17315603
[TBL] [Abstract][Full Text] [Related]
16. Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
McCullough PA; Bakris GL; Owen WF; Klassen PS; Califf RM
Am Heart J; 2004 Aug; 148(2):243-51. PubMed ID: 15308993
[TBL] [Abstract][Full Text] [Related]
17. Slowing progression along the renal disease continuum.
Kopyt NP
J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
[TBL] [Abstract][Full Text] [Related]
18. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
19. [Diabetic nephropathy: new insights into diagnosis, prevention and treatment].
Rheinberger M; Böger CA
Dtsch Med Wochenschr; 2014 Apr; 139(14):704-6. PubMed ID: 24668430
[No Abstract] [Full Text] [Related]
20. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
Chantrel F; Bouiller M; Kolb I; Hannedouche T
Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
